Sex Drugs and Corporate Ventriloquism: How to Evaluate Science Policies Intended to Manage Industry-Funded Bias

2018/07/17 by Bennett Holman, Sally Geislar · 3 citations
Pharmacology, Toxicology and Pharmaceutics · Medicine · #Pharmaceutical industry and healthcare #Sex and Gender in Healthcare #Reproductive Health and Contraception

paper · doi:10.1086/699713

Abstract

Abstract “Female sexual dysfunction” is the type of contested disease that has sparked concern about the role of the pharmaceutical industry in medical science. Many policies have been proposed to manage industry influence without carefully evaluating whether the proposed policies would be successful. We consider a proposal for incorporating citizen stakeholders into scientific research and show, via a detailed case study of the pharmaceutical regulation of flibanserin (misleadingly marketed as the “female Viagra”), that such programs can be co-opted. In closing, we use Holman’s asymmetric arms race framework as a tool for evaluating policies in industry-funded science.

Cited by

• Commercial influences on patient and public involvement: a renewed call for research and action
• CRISPR, APGAR and Cancer Screening: Public Engagement, Controversy and Misaligned Values
• Conflicts of interest in submissions and testimonies to an Australian parliamentary inquiry on menopause

Related

• Making a ‘sex-difference fact’: Ambien dosing at the interface of policy, regulation, women’s health, and biology
• Sexed Politics, Histories, and Futures
• The Science for Profit Model—How and why corporations influence science and the use of science in policy and practice
• Women’s Experiences of In-Person Sexual and Reproductive Health Services: A protocol for a rapid Qualitative Evidence Synthesis to Explore the Potential Role for Community Pharmacies
• Applying the new SABV (sex as a biological variable) policy to research and clinical care